vs
Side-by-side financial comparison of Biogen (BIIB) and Evercore Inc. (EVR). Click either name above to swap in a different company.
Biogen is the larger business by last-quarter revenue ($2.5B vs $1.4B, roughly 1.8× Evercore Inc.). Evercore Inc. runs the higher net margin — 23.0% vs 12.9%, a 10.1% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (100.3% vs 2.0%). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (42.2% CAGR vs 0.3%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
BIIB vs EVR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $1.4B |
| Net Profit | $319.5M | $322.7M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 12.9% | 23.0% |
| Revenue YoY | 2.0% | 100.3% |
| Net Profit YoY | 32.8% | 106.1% |
| EPS (diluted) | $2.15 | $7.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.5B | $1.4B | ||
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $2.5B | $1.0B | ||
| Q2 25 | $2.6B | $838.0M | ||
| Q1 25 | $2.4B | $699.0M | ||
| Q4 24 | $2.5B | $979.5M | ||
| Q3 24 | $2.5B | $738.4M | ||
| Q2 24 | $2.5B | $693.4M |
| Q1 26 | $319.5M | $322.7M | ||
| Q4 25 | $-48.9M | $204.0M | ||
| Q3 25 | $466.5M | $144.6M | ||
| Q2 25 | $634.8M | $97.2M | ||
| Q1 25 | $240.5M | $146.2M | ||
| Q4 24 | $266.7M | $140.4M | ||
| Q3 24 | $388.5M | $78.4M | ||
| Q2 24 | $583.6M | $73.8M |
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | 24.2% | ||
| Q3 25 | 22.0% | 20.8% | ||
| Q2 25 | 28.1% | 18.0% | ||
| Q1 25 | 12.8% | 16.0% | ||
| Q4 24 | 11.9% | 21.8% | ||
| Q3 24 | 18.3% | 16.7% | ||
| Q2 24 | 28.3% | 15.9% |
| Q1 26 | 12.9% | 23.0% | ||
| Q4 25 | -2.1% | 15.7% | ||
| Q3 25 | 18.4% | 13.8% | ||
| Q2 25 | 24.0% | 11.6% | ||
| Q1 25 | 9.9% | 20.9% | ||
| Q4 24 | 10.9% | 14.3% | ||
| Q3 24 | 15.8% | 10.6% | ||
| Q2 24 | 23.7% | 10.6% |
| Q1 26 | $2.15 | $7.20 | ||
| Q4 25 | $-0.35 | $4.80 | ||
| Q3 25 | $3.17 | $3.41 | ||
| Q2 25 | $4.33 | $2.36 | ||
| Q1 25 | $1.64 | $3.48 | ||
| Q4 24 | $1.82 | $3.32 | ||
| Q3 24 | $2.66 | $1.86 | ||
| Q2 24 | $4.00 | $1.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.4B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $18.7B | — |
| Total Assets | $29.5B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $1.7B |
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.3B | $2.0B | ||
| Q3 25 | $18.2B | $1.8B | ||
| Q2 25 | $17.6B | $1.7B | ||
| Q1 25 | $17.0B | $1.5B | ||
| Q4 24 | $16.7B | $1.7B | ||
| Q3 24 | $16.4B | $1.6B | ||
| Q2 24 | $15.9B | $1.5B |
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $5.4B | ||
| Q3 25 | $29.2B | $4.4B | ||
| Q2 25 | $28.3B | $3.7B | ||
| Q1 25 | $28.0B | $3.3B | ||
| Q4 24 | $28.0B | $4.2B | ||
| Q3 24 | $28.3B | $3.6B | ||
| Q2 24 | $26.8B | $3.3B |
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | $594.3M | — |
| FCF MarginFCF / Revenue | 24.0% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.4B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $807.5M | ||
| Q3 25 | $1.3B | $560.9M | ||
| Q2 25 | $160.9M | $437.7M | ||
| Q1 25 | $259.3M | $-549.7M | ||
| Q4 24 | $760.9M | $686.4M | ||
| Q3 24 | $935.6M | $234.5M | ||
| Q2 24 | $625.8M | $348.5M |
| Q1 26 | $594.3M | — | ||
| Q4 25 | $468.0M | $798.6M | ||
| Q3 25 | $1.2B | $541.5M | ||
| Q2 25 | $134.3M | $411.7M | ||
| Q1 25 | $222.2M | $-569.3M | ||
| Q4 24 | $721.6M | $673.1M | ||
| Q3 24 | $900.6M | $226.6M | ||
| Q2 24 | $592.3M | $340.7M |
| Q1 26 | 24.0% | — | ||
| Q4 25 | 20.5% | 61.6% | ||
| Q3 25 | 48.4% | 51.8% | ||
| Q2 25 | 5.1% | 49.1% | ||
| Q1 25 | 9.1% | -81.4% | ||
| Q4 24 | 29.4% | 68.7% | ||
| Q3 24 | 36.5% | 30.7% | ||
| Q2 24 | 24.0% | 49.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 0.7% | ||
| Q3 25 | 1.8% | 1.9% | ||
| Q2 25 | 1.0% | 3.1% | ||
| Q1 25 | 1.5% | 2.8% | ||
| Q4 24 | 1.6% | 1.4% | ||
| Q3 24 | 1.4% | 1.1% | ||
| Q2 24 | 1.4% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.96× | ||
| Q3 25 | 2.73× | 3.88× | ||
| Q2 25 | 0.25× | 4.50× | ||
| Q1 25 | 1.08× | -3.76× | ||
| Q4 24 | 2.85× | 4.89× | ||
| Q3 24 | 2.41× | 2.99× | ||
| Q2 24 | 1.07× | 4.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
